View More View Less
  • 1 Debreceni Egyetem, Népegészségügyi Kar, Debrecen, Kassai u. 26., 4028
Restricted access

Absztrakt

A polycystás ovarium szindróma a nők leggyakoribb endokrin és anyagcsere-betegsége. A szindróma gyakran társul elhízással, hyperinsulinaemiával, növeli a cukorbetegség, a lipidanyagcsere-zavarok és a cardiovascularis betegségek kockázatát. Tekintettel a kórkép komplex megjelenésére és a terápiás eljárásokban jelenleg tapasztalható jelentős eltérésekre, a betegek gondozásához, az optimális terápia megválasztásához interdiszciplináris, gyermekgyógyász, belgyógyász, nőgyógyász, endokrinológus, bőrgyógyász, pszichológus és onkológus együttműködése és a rendelkezésre álló legmagasabb bizonyítékon alapuló preventív és terápiás technológiák alkalmazása szükséges, amely a diagnosztikus eredményeket és a beteg preferenciáit is figyelembe veszi. Ezzel javulna a terápia eredményessége, hatékonysága, a betegek biztonsága, életminősége és várható élettartama. A cikk a rendelkezésre álló legmagasabb bizonyítékok, szisztematikus irodalmi áttekintések és metaanalízisek felhasználásával ismerteti a kórképhez társuló klinikai és anyagcsere-szövődmények megelőzéséhez és terápiájához szükséges bizonyítékokat és a bizonyítékokon alapuló ellátás alapelveit. Orv. Hetil., 2015, 156(50), 2018–2026.

  • 1

    Sirmans, S. M., Pate, K. A.: Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin. Epidemiol., 2014, 6, 1–13.

  • 2

    Moran, L., Teede, H.: Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum. Reprod. Update, 2009, 15(4), 477–488.

  • 3

    Dunaif, A., Fauser, B. C.: Renaming PCOS – a two-state solution. J. Clin. Endocrinol. Metab., 2013, 98(11), 4325–4328.

  • 4

    Moran, L. J., Misso, M. L., Wild, R. A., et al.: Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update, 2010, 16(4), 347–363.

  • 5

    Macut, D., Bačević, M., Božić-Antić, I., et al.: Predictors of subclinical cardiovascular disease in women with polycystic ovary syndrome: interrelationship of dyslipidemia and arterial blood pressure. Int. J. Endocrinol., 2015, 2015, 812610. [Epub 2015 Mar 24.] http://dx.doi.org/10.1155/2015/812610

  • 6

    Conway, G., Dewailly, D., Diamanti-Kandarakis, E., et al.: The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur. J. Endocrinol., 2014, 171(4), P1–P29.

  • 7

    Legro, R. S., Arslanian, S. A., Ehrmann, D. A., et al.: Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab., 2013, 98(12), 4565–4592.

  • 8

    Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., et al.: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2012, 55(6), 1577–1596.

  • 9

    Mancia, G., Fagard, R., Narkiewicz, K., et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens., 2013, 31(7), 1281–1357.

  • 10

    Bianchi, C., Miccoli, R., Trombetta, M., et al.: Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study. J. Clin. Endocrinol. Metab., 2013, 98(5), 2100–2105.

  • 11

    Sesti, G., Fiorentino, T. V., Succurro, E., et al.: Elevated 1-h post-load plasma glucose levels in subjects with normal glucose tolerance are associated with unfavorable inflammatory profile. Acta Diabetol., 2014, 51(6), 927–932.

  • 12

    Gruber, A., Nasser, K., Smith, R., et al.: Diabetes prevention: is there more to it than lifestyle changes? Int. J. Clin. Pract., 2006, 60(5), 590–594.

  • 13

    Rydén, L., Grant, P. J., Anker, S. D., et al.: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur. Heart J., 2013, 34(39), 3035–3087.

  • 14

    Vandvik, P. O., Lincoff, A. M., Gore, J. M., et al.: Primary and secondary prevention of cardiovascular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl.), e637S–e668S.

  • 15

    Lim, S. S., Davies, M. J., Norman, R. J., et al.: Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update, 2012, 18(6), 618–637.

  • 16

    Traub, M. L.: Assessing and treating insulin resistance in women with polycystic ovarian syndrome. World J. Diabetes, 2011, 2(3), 33–40.

  • 17

    Alebić, M. Š., Bulum, T., Stojanović, N., et al.: Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria. Endocrine, 2014, 47(2), 625–630.

  • 18

    Hücking, K., Watanabe, R. M., Stefanovski, D., et al.: OGTT-derived measures of insulin sensitivity are confounded by factors other than insulin sensitivity itself. Obesity, 2008, 16(8), 1938–1945.

  • 19

    Farquhar, C. M., Birdsall, M. A., Manning, P., et al.: The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust. N. Z. J. Obstet. Gynaecol., 1994, 34(1), 67–72.

  • 20

    Işik, A. Z., Gülekli, B., Zorlu, C. G., et al.: Endocrinological and clinical analysis of hyperprolactinaemic patients with and without ultrasonically diagnosed polycystic ovarian changes. Gynecol. Obstet. Invest., 1997, 43(3), 183–185.

  • 21

    Marshall, J. C., Dunaif, A.: Should all women with PCOS be treated for insulin resistance? Fertil. Steril., 2012, 97(1), 18–22.

  • 22

    Wagner, R., Häring, H. U., Fritsche, A.: Phänotypen des prädiabetes und des typ-2-diabetes. Dtsch. Med. Wochenschr., 2014, 139(21), 1109–1113.

  • 23

    Salpeter, S. R., Buckley, N. S., Kahn, J. A., et al.: Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am. J. Med., 2008, 121(2), 149–157.e2

  • 24

    Krysiak, R., Okopien, B.: Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Basic Clin. Pharmacol. Toxicol., 2015, 116(3), 251–256.

  • 25

    Gibson, C. D., Karmally, W., McMahon, D. J., et al.: Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obes. Metab., 2012, 14(4), 335–340.

  • 26

    Shivaprasad, C., Kalra, S.: Bromocriptine in type 2 diabetes mellitus. Indian J. Endocr. Metab., 2011, 15(Suppl. 1), S17–S24.

  • 27

    Arentz, S., Abbott, J. A., Smith, C. A., et al.: Herbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findings. BMC Complement. Altern. Med., 2014, 14(1), 511.

  • 28

    Ried, K.: Chinese herbal medicine for female infertility: An updated meta-analysis. Complement. Ther. Med., 2015, 23(1), 116–128.

  • 29

    Bjelakovic, G., Gluud, L. L., Nikolova, D., et al.: Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst. Rev., 2014, (1), CD007470.

  • 30

    Ardabili, H. R., Gargari, B. P., Farzadi, L.: Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency. Nutr. Res., 2012, 32(3), 195–201.

  • 31

    Kim, J. J., Choi, Y. M.: Dyslipidemia in women with polycystic ovary syndrome. Obstet. Gynecol. Sci., 2013, 56(3), 137–142.

  • 32

    Gao, L., Zhao, F. L., Li, S. C.: Statin is a reasonable treatment option for patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Exp. Clin. Endocrinol. Diabetes, 2012, 120(6), 367–375.

  • 33

    Raval, A. D., Hunter, T., Stuckey, B., et al.: Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst. Rev., 2011, (10), CD008565.

  • 34

    European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC): PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system. EMA/196502/2014. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/04/WC500165197.pdf

  • 35

    Bajuk Studen, K., Jensterle Sever, M., Pfeifer, M.: Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome. In: Macut, D., Pfeifer, M., Yildiz, B. O., et al. (eds.): Polycystic ovary syndrome. Novel insights into causes and therapy. Front. Horm. Res. Basel, Karger, 2013, 40, 64–82.

  • 36

    Recommendations of the VI. Hungarian Cardiovascular Consensus Conference. [VIth Magyar Kardiovaszkuláris Konszenzus Konferencia ajánlása.] Metabolizmus, 2015, 13(1). [Hungarian]

  • 37

    Barry, J. A., Azizia, M. M., Hardiman, P. J.: Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update, 2014, 20(5), 748–758.

  • 38

    Shafiee, M. N., Khan, G., Ariffin, R., et al.: Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? Gynecol. Oncol., 2014 132(1), 248–253.

  • 39

    Calogero, A. E., Calabrò, V., Catanuso, M., et al.: Understanding polycystic ovarian syndrome pathogenesis: an updated of its genetic aspects. J. Endocrinol. Invest., 2011, 34(8), 630–644.

  • 40

    Dowling, A. R., Nedorezov, L. B., Qiu, X., et al.: Genetic factors modulate the impact of pubertal androgen excess on insulin sensitivity and fertility. PLoS ONE, 2013, 8(11), e79849.

  • 41

    Louwers, Y. V., Lao, O., Fauser, B. C., et al.: The impact of self-reported ethnicity versus genetic ancestry on phenotypic characteristics of polycystic ovary syndrome (PCOS). J. Clin. Endocrinol. Metab., 2014, 99(10), E2107–E2116.

  • 42

    Grobbee, D. E., Miettinen, O. S.: Clinical epidemiology. Introduction to the discipline. Neth. J. Med., 1995, 47(1), 2–5.

  • 43

    Straus, S. E., Sackett, D. L.: Using research findings in clinical practice. BMJ, 1998, 317(7154), 339–342.

  • 44

    Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009). Centre for Evidence-based Medicine, 2015.

  • 45

    Song, F., Parekh, S., Hooper, L., et al.: Dissemination and publication of research findings: an updated review of related biases. Health Technol. Assess., 2010, 14(8), iii, ix–xi, 1–193.

  • 46

    Schmucker, C., Bluemle, A., Briel, M., et al.: A protocol for a systematic review on the impact of unpublished studies and studies published in the gray literature in meta-analyses. Syst. Rev., 2013, 2, 24.

  • 47

    Sweeney, K. G., MacAuley, D., Gray, D. P.: Personal significance: the third dimension Lancet, 1998, 351(9096), 134–136.

  • 48

    Centre for evidence-based medicine. Toronto. http://ktclearinghouse.ca/cebm/practise/ca/calculators/ortonnt

  • 49

    Bereczki, D., Mogyorósy, Zs.: Critical appraisal of the literature. In: Gődény, S. (ed.): Improvement of clinical effectivenes in healthcare. [Irodalomkutatás, az irodalom kritikus elemzése. In: Gődény, S. (szerk.): A klinikai hatékonyság fejlesztése az egészségügyben.] Pro Die Kiadó, Budapest, 2007. [Hungarian]

  • 50

    Greenhalgh, T.: How to read a paper: papers that report drug trials. BMJ, 1997, 315(7106), 480–483.

  • 51

    Grimes, D. A., Schulz, K. F.: Surrogate end points in clinical research: hazardous to your health. Obstet. Gynecol., 2005, 105(5 Pt 1), 1114–1118.

  • 52

    Kidson, W.: Polycystic ovary syndrome: a new direction in treatment. Med. J. Aust., 1998, 169(10), 537–540.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2021 14 1 1
Feb 2021 8 2 4
Mar 2021 29 2 0
Apr 2021 30 0 0
May 2021 9 0 0
Jun 2021 8 0 0
Jul 2021 0 0 0